Literature DB >> 23680144

Releasing the block: setting differentiation free with mutant IDH inhibitors.

Christopher J Pirozzi1, Zachary J Reitman, Hai Yan.   

Abstract

Hotspot mutations in IDH1 and IDH2 cause a differentiation block that can promote tumorigenesis. Two recent papers reported that small molecules targeting mutant IDH1 or mutant IDH2 release this differentiation block and/or impede tumor growth, providing a proof-of-concept that mutant IDHs are therapeutically targetable and that their effects are reversible.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23680144      PMCID： PMC4465106          DOI： 10.1016/j.ccr.2013.04.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

2.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

3.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

Authors:  Masato Sasaki; Christiane B Knobbe; Joshua C Munger; Evan F Lind; Dirk Brenner; Anne Brüstle; Isaac S Harris; Roxanne Holmes; Andrew Wakeham; Jillian Haight; Annick You-Ten; Wanda Y Li; Stefanie Schalm; Shinsan M Su; Carl Virtanen; Guido Reifenberger; Pamela S Ohashi; Dwayne L Barber; Maria E Figueroa; Ari Melnick; Juan-Carlos Zúñiga-Pflücker; Tak W Mak
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

4.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

5.  A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Authors:  Christopher G Duncan; Benjamin G Barwick; Genglin Jin; Carlo Rago; Priya Kapoor-Vazirani; Doris R Powell; Jen-Tsan Chi; Darell D Bigner; Paula M Vertino; Hai Yan
Journal:  Genome Res       Date:  2012-08-16       Impact factor: 9.043

6.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

7.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

8.  Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Authors:  Genglin Jin; Christopher J Pirozzi; Lee H Chen; Giselle Y Lopez; Christopher G Duncan; Jie Feng; Ivan Spasojevic; Darell D Bigner; Yiping He; Hai Yan
Journal:  Oncotarget       Date:  2012-08

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

10.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714
  10 in total
  11 in total

1.  Inhibitors of Mutant IDH for the Treatment of Cancer.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-10-07       Impact factor: 4.345

Review 2.  Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?

Authors:  R Brooks Robey; Judith Weisz; Nancy B Kuemmerle; Anna C Salzberg; Arthur Berg; Dustin G Brown; Laura Kubik; Roberta Palorini; Fahd Al-Mulla; Rabeah Al-Temaimi; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Graeme P Williams; Leroy Lowe; Joel Meyer; Francis L Martin; William H Bisson; Ferdinando Chiaradonna; Elizabeth P Ryan
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

3.  Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.

Authors:  Zhongxu An; Vivek Tiwari; Sandeep K Ganji; Jeannie Baxter; Michael Levy; Marco C Pinho; Edward Pan; Elizabeth A Maher; Toral R Patel; Bruce E Mickey; Changho Choi
Journal:  Magn Reson Med       Date:  2017-08-22       Impact factor: 4.668

4.  Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.

Authors:  Malak S Abedalthagafi; Michael P Wu; Parker H Merrill; Ziming Du; Terri Woo; Shu-Hsien Sheu; Shelley Hurwitz; Keith L Ligon; Sandro Santagata
Journal:  J Pathol       Date:  2016-03       Impact factor: 7.996

5.  Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.

Authors:  Wen Cheng; Xiufang Ren; Chuanbao Zhang; Jinquan Cai; Sheng Han; Anhua Wu
Journal:  Mol Neurobiol       Date:  2016-09-30       Impact factor: 5.590

6.  Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Authors:  Sichen Li; Reshmi Chowdhury; Fei Liu; Arthur P Chou; Tie Li; Reema R Mody; Jerry J Lou; Weidong Chen; Jean Reiss; Horacio Soto; Robert Prins; Linda M Liau; Paul S Mischel; Phioanh L Nghiemphu; William H Yong; Timothy F Cloughesy; Albert Lai
Journal:  Clin Cancer Res       Date:  2014-09-15       Impact factor: 12.531

7.  Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.

Authors:  Chaitanya R Churi; Rachna Shroff; Ying Wang; Asif Rashid; HyunSeon C Kang; Jacqueline Weatherly; Mingxin Zuo; Ralph Zinner; David Hong; Funda Meric-Bernstam; Filip Janku; Christopher H Crane; Lopa Mishra; Jean-Nicholas Vauthey; Robert A Wolff; Gordon Mills; Milind Javle
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

8.  Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Mia Y Platt; Amir T Fathi; Darrell R Borger; Andrew M Brunner; Robert P Hasserjian; Leonora Balaj; Amy Lum; Stephen Yip; Dora Dias-Santagata; Zongli Zheng; Long P Le; Timothy A Graubert; A John Iafrate; Valentina Nardi
Journal:  J Mol Diagn       Date:  2015-08-30       Impact factor: 5.341

9.  Driver mutations of cancer epigenomes.

Authors:  David M Roy; Logan A Walsh; Timothy A Chan
Journal:  Protein Cell       Date:  2014-03-14       Impact factor: 14.870

10.  IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Authors:  Houria Debarri; Delphine Lebon; Christophe Roumier; Meyling Cheok; Alice Marceau-Renaut; Olivier Nibourel; Sandrine Geffroy; Nathalie Helevaut; Philippe Rousselot; Bérengère Gruson; Claude Gardin; Marie-Lorraine Chretien; Shéhérazade Sebda; Martin Figeac; Céline Berthon; Bruno Quesnel; Nicolas Boissel; Sylvie Castaigne; Hervé Dombret; Aline Renneville; Claude Preudhomme
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.